We suspect this quarter will ultimately be received poorly by the market given headline margin weakness across the two ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...

The study, led by Dr. Luca Busetto from the University of Padova in Italy and colleagues from Eli Lilly and Company that manufacture tirzepatide, is a continuation of the SURMOUNT-1 phase 3 trial ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

According to a new study, a once-weekly dose of tirzepatide can lead to significant, sustained weight loss for up to 3 years in adults with overweight or obesity who do not have diabetes.

The Guardian reports the nonprofit group the Center for Environmental Health has taken legal action against dozens of retailers for using high levels of a hormone-disrupting chemical in their ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Shares of Eli Lilly LLY soared 14.3% on April 17 after data from a late-stage study showed that orforglipron achieved the primary goal of significantly reducing A1C levels compared to placebo at ...